[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arrhythmogenic-right-ventricular-dysplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arrhythmogenic-right-ventricular-dysplasia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,76,112,148,175],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100455378","local-inflammation-in-arrhythmogenic-right-ventricular-cardiomyopathy-100455378",false,"NCT05209776","Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy","LI-ARVC","Inclusion Criteria:\n\n* For cases:\n\n  * Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria)\n  * Admitted for right ventricle electrophysiologic mapping\n* For controls \\* Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts.\n\nExclusion Criteria:\n\n* Diagnostic of systemic chronic inflammatory disease\n* Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease.\n* Taking immunosuppressant or immunomodulating medications","ALL","18 Years","99 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.",[27],"Arrhythmogenic Right Ventricular Dysplasia",[29,30,31,32,33,34,35,36],"Cardiac Electrophysiologic Techniques","Inflammation","Cytokines","Interleukin-1","Interleukin-6","Interleukin-10","Transforming Growth Factor beta","Tumor Necrosis Factor-alpha","RECRUITING","2026-05-28",{"date":40,"type":41},"2026-06-01","ACTUAL",{"date":43,"type":41},"2022-02-01",{"date":45,"type":21},"2027-02",{"name":47,"class":48},"University Hospital, Toulouse","OTHER",1,{"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":49},"100382312","distribution-of-cell-cell-junction-proteins-in-arrhythmic-disorders-100382312",true,"NCT04257994","Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders","Analysis of Distribution of Cell-cell Junction Proteins in Buccal Smear Samples From Patients With Arrhythmic Disorders and Family Members at Risk as a Means for Diagnosis","Inclusion Criteria:• Participants will include patients diagnosed with a heritable arrhythmic disorder (including arrhythmogenic, hypertrophic and dilated cardiomyopathy, cardiac sarcoidosis as well as cardiac channelopathies; Long QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia) followed at the Inherited Cardiac Conditions (ICC) service of St. George's University Hospitals NHS Foundation Trust.\n\n* Family members of victims of SCD evaluated at the same clinic for risk assessment and diagnosis. These groups include both individuals with clear disease manifestation (termed \"affected\") as shown by conventional diagnostic approaches (electrocardiography, echocardiography, cardiac MRI, Holter monitoring) as well as potential carriers of disease-causing mutations who, however, may not\u002Fnot yet manifest any overt sign of cardiovascular abnormalities (termed \"carriers\"). These are typically family members of probands diagnosed with a heritable arrhythmic disorder or family members of a sudden cardiac death victim.\n* All individuals that fall in the above categories will be included regardless of their management (medication, devices, and surgical procedures).\n* Individuals with co-existing conditions will also be included and their medical history will be taken into account when interpreting the results of the immunohistochemical analysis.\n* Adult individuals (\\>18 years of age).\n* Pregnant women will be included as the approach used is not in any way harmful or uncomfortable.\n* All individuals must have provided the study team with a signed informed consent in order to participate in the study.\n\nExclusion Criteria:• Children under 18 years of age\n\n* Individuals lacking decisional capacity.\n* Individuals with non-heritable, non-arrhythmic cardiac disorders (such as ischemic heart disease or inflammatory disorders) followed at St. George's University Hospitals NHS Foundation Trust.\n* Non-English speakers will be excluded from the study unless a translator is present who can thoroughly explain to them the research question\u002Fplan in order for them to provide an informed consent.",{"count":59,"type":21},26,"OBSERVATIONAL","Every week in the UK, 12 apparently healthy and fit individuals under the age of 35 die suddenly, a tragic event known as sudden cardiac death (SCD). The investigators have shown that heritable cardiac disorders affect the distribution of proteins at the cardiac cell-cell junctions, the areas where cardiac cells are mechanically and electrically coupled. This knowledge has helped the investigators diagnose specific heart disorders in individuals thus reducing the risk and incidence of SCD. Yet, the primary material required is a heart sample. A heart biopsy is an invasive process that comes with risks and is not performed unless absolutely necessary. And it is impossible to obtain a heart sample from an individual that may be carrying a disease-causing mutation (and hence be at risk of SCD) but does not yet show evidence of disease manifestation. The investigators recently showed that buccal cells show changes in protein distribution equivalent to those exhibited by the heart,hence providing them with a surrogate tissue for the myocardium. The investigators aim to use buccal smears as a means to identify those at risk of SCD. Patients regularly seen at the cardiology clinics at St. George's Hospital can participate in the study. The investigators shall take a buccal smear simply by rubbing a soft brush at the inside of their cheek and smearing it on a slide. Most individuals willing to participate in the study will only have to provide the investigators with a sample once. However, in selected cases (for instance, if the patients show disease progression or have a change in medication) they may be asked to provide the investigators with a subsequent sample during one of their scheduled follow-up visits. The process takes only a few seconds, is totally risk- and pain-free and it is anticipated to have great implications in diagnosis and patient management.",[27,63,64],"Brugada Syndrome","Cardiac Channelopathy",[66],"cardiac arrhythmias","2026-05-07",{"date":69,"type":41},"2026-05-08",{"date":71,"type":41},"2017-10-15",{"date":73,"type":21},"2027-06-30",{"name":75,"class":48},"St. George's Hospital, London",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":60,"phases":4,"briefSummary":86,"conditions":87,"keywords":100,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100558055","national-network-for-cardiovascular-genomics-advancing-cardiovascular-healthcare-for-hereditary-diseases-in-brazils-unified-health-system-through-a-multicenter-registry-100558055","NCT06546137","National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry","RENOMICA-Hcor","Inclusion Criteria:\n\n* Clinical diagnosis of a hereditary cardiovascular disease according to current clinical guidelines\n* Agree to receive genetic counseling\n* Sign informed consent form\n* Provide the information required in the case report form\n\nExclusion Criteria:\n\n* Signature absent from informed consent form\n* Inadequate buccal swab (sample may be collected twice)",{"count":84,"type":21},1211,"6 Months","The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data. The main questions it aims to answer are:\n\nWhich genes are most commonly affected? What is the frequency of these genetic alterations in our population? Participants will be interviewed in routine medical care visits and their DNA will be sequenced.",[88,89,90,27,91,92,93,94,95,96,97,63,98,99],"Cardiomyopathy, Hypertrophic","Cardiomyopathy, Dilated","Cardiomyopathy Restrictive","Non-Compaction Cardiomyopathy","Familial Hypercholesterolemia","Marfan Syndrome","Ehlers-Danlos Syndrome, Vascular Type","Loeys-Dietz Syndrome","Long QT Syndrome","Short Qt Syndrome","Catecholaminergic Polymorphic Ventricular Tachycardia","Sudden Cardiac Death",[101,102],"hereditary cardiovascular diseases","whole genome sequencing","2026-05-04",{"date":69,"type":41},{"date":106,"type":41},"2025-04-30",{"date":108,"type":21},"2026-08-31",{"name":110,"class":48},"Hospital do Coracao",27,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":53,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100289553","mayo-avc-registry-and-biobank-100289553","NCT03049254","Mayo AVC Registry and Biobank","Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy","Inclusion Criteria:\n\n* Patients with a diagnosis of a non-MI SCA who survived\n* Patients with a non-MI SCD\n* Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected\n* Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)\n\nExclusion Criteria:\n\n* Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease\n* Significant coronary artery disease (Epicardial coronary artery stenosis \\>50%) which can explain degree of LV dysfunction\n* Those unwilling to provide written consent or assent",{"count":120,"type":21},1000,"Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death.\n\nThe Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples.\n\nObjectives of the study:\n\n1. Discover new genes or altered genes (variants) which cause AVC\n2. Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation)\n3. Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data.\n4. Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies",[123,124,125,126,127,99,27,128,129,130,131,132,133,134,135,136,137],"Arrhythmogenic Right Ventricular Cardiomyopathy","Cardiomyopathies","Heart Diseases","Cardiovascular Diseases","Sudden Cardiac Arrest","Arrhythmogenic Ventricular Cardiomyopathy","Familial Dilated Cardiomyopathy","Cardiovascular Abnormalities","Sarcoidosis","Cardiac Arrhythmia","Cardiac Sarcoidosis","Myocarditis","Inflammatory Cardiomyopathy","Ventricular Tachycardia","Right Ventricular Outflow Tract Ventricular Tachycardia","2026-04-22",{"date":140,"type":41},"2026-04-27",{"date":142,"type":41},"2018-02-09",{"date":144,"type":21},"2027-03",{"name":146,"class":48},"Mayo Clinic",2,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100331289","phase-2-blockade-of-the-renin-angiotensin-aldosterone-system-in-patients-with-arvd-100331289","NCT03593317","Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD","Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD: a Double-blind Multicentre Prospective Randomized Study.","BRAVE","Inclusion Criteria:\n\n* \\>18years old\n* Diagnosis of ARVD based on Task Force criteria. Two major criteria: 1 morphologic and one rhythmic or 1 major and 2 minor criteria established by the European Society of Cardiology\u002FInternational Society and Federation of Cardiology.\n* Left Ventricular Ejection Fraction \\>40%\n* Written informed consent.\n\nExclusion Criteria:\n\n* Patients under judicial protection.\n* Female patient who is pregnant or lactating, or is of child bearing potential (defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if ≤ 55 years or 12 months if \\> 55 years) and who did not agree to use highly effective methods of birth control throughout the study.\n* No health insurance.\n* Right heart failure patient (RV volume\\>150ml).\n* Spironolactone contraindication: anuria, hyperkalemia (K+\\>5 mmol\u002Fl), renal failure (DFGCréat\\>22 mL\u002Fmin\u002F1,73 m2), end-stage liver failure, Addison's Disease, hypersensitivity to spironolactone or to any of the excipients (patients with galactose intolerance, lapp lactase deficiency or glucose or galactose malabsorption syndrome), association with eplerenone, association with other hyperkalemic diuretics, association with potassium salts, not recommended in cirrhotic patients (natraemia\\\u003C125 mmol\u002Fl) or in patients likely to present an acidosis.\n* Mandatory indication for a combination of ACE inhibitor and sartan or renin inhibitor (each authorized separately).\n* Acute phase of systemic disease.\n* Uncompensated hypothyroidism.\n* Acute hyperthyroidism.\n* Normal right ventricular volume.\n* Heart transplantation.\n* Swallowing disorders.\n* Participation in any other interventional clinical investigation that may have an impact on our study.",{"count":157,"type":21},120,[159],"PHASE2","Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy characterized by the progressive replacement of cardiomyocytes by fatty and fibrous tissue in the right ventricle (RV). These infiltrations lead to cardiac electrical instability and ventricular arrhythmia.\n\nCurrent treatment for ARVD is empirical and essentially based on treatment of arrhythmia. Thus, there is no validated treatment that will prevent the deterioration of the RV function in patients with ARVD.\n\nThe investigator's hypothesis is that the use of anti-fibrotic medications will prevent or at least reduce the deterioration of the RV function. The aim of this project is to evaluate the effect of spironolactone, a Potassium-sparing diuretic on ventricular myocardial remodeling and on arrhythmia burden in patients with ARVD.\n\nThe trial is a double-blind parallel multicenter prospective randomized phase II drug study. Patients will be randomized in the two groups: spironolactone or placebo. 13 centers in France will enroll the 120 patients (60 per group). Patients will be followed for 3 years (6 months, 1 year and 3 years) with all examinations (ECG, HA ECG, 24-hour Holter, trans-thoraciqc echocardiography (TTE), biological analyses) according to standard of care. A decrease in right and\u002For left ventricular deterioration and in arrhythmia burden are expected in ARVD patients treated with spironolactone. This reduction will improve the quality of life of patients and will reduce the number of hospitalizations and the risk of terminal heart failure.",[27],[163,164],"Heart Failure","Right ventricle","2026-02-05",{"date":167,"type":41},"2026-02-09",{"date":169,"type":41},"2024-12-20",{"date":171,"type":21},"2029-12",{"name":173,"class":48},"Hospices Civils de Lyon",13,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":185,"studyType":60,"phases":4,"briefSummary":186,"conditions":187,"keywords":195,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":49},"100479320","clinical-cohort-study---trust-100479320","NCT05521451","Clinical Cohort Study - TRUST","Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg","TRUST","Inclusion Criteria:\n\n* Cardiac arrhythmia, including congenital cardiac arrhythmia diagnosed at baseline or high risk for cardiac arrhythmia\n* Age ≥ 18 years\n* Written informed consent\n* Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents and interview without translation\n* Physical or psychological incapability to cooperate in the investigation",{"count":184,"type":21},5000,"10 Years","The \"Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg\" (TRUST) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac arrhythmias or at high risk for cardiac arrhythmias. The design enables prospective, low-threshold, near complete inclusion of patients with arrhythmias treated at the UHZ. Collection of routine follow-up data, detailed procedural information and systematic biobanking will enable precise and robust phenotyping.",[188,189,190,136,191,27,96,63,192,98,193,194],"Arrhythmias, Cardiac","Atrial Fibrillation","Atrial Flutter","Atrial Tachycardia","Supraventricular Tachycardia","Torsades De Pointes","Atrial Cardiomyopathy",[196,197,132,198,199,200,194],"Catheter Ablation","Biomarkers","eHealth","Digital Cardiology","Echocardiography","2025-03-25",{"date":203,"type":41},"2025-03-30",{"date":205,"type":41},"2021-03-17",{"date":207,"type":21},"2031-12-31",{"name":209,"class":48},"Universitätsklinikum Hamburg-Eppendorf"]